

Risk-adapted therapy for young children with medulloblastoma: molecular outcomes from a multicentre, phase 2 trial

Lancet Oncology, The
19, 768-784

DOI: [10.1016/s1470-2045\(18\)30204-3](https://doi.org/10.1016/s1470-2045(18)30204-3)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Are molecular subgroups of medulloblastomas really prognostic?. <i>Current Opinion in Neurology</i> , 2018, 31, 747-751.	1.8	2
2	Interrogating molecular data for medulloblastoma risk stratification. <i>Lancet Oncology</i> , The, 2018, 19, 1548-1549.	5.1	3
3	Genetic Abnormalities, Clonal Evolution, and Cancer Stem Cells of Brain Tumors. <i>Medical Sciences (Basel, Switzerland)</i> , 2018, 6, 85.	1.3	9
4	New stratification for early childhood medulloblastoma. <i>Pediatric Medicine</i> , 2018, 1, 10-10.	1.1	2
5	Medulloblastoma in infants: the never-ending challenge. <i>Lancet Oncology</i> , The, 2018, 19, 720-721.	5.1	7
6	Clinical and pre-clinical utility of genomics in medulloblastoma. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 633-647.	1.4	13
7	Infant medulloblastoma – learning new lessons from old strata. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 659-660.	12.5	15
8	Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 829-838.	1.1	6
9	Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours. <i>Nature Reviews Cancer</i> , 2019, 19, 420-438.	12.8	98
10	Clinical Utility of GliOSeq Next-Generation Sequencing Test in Pediatric and Young Adult Patients With Brain Tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 694-702.	0.9	3
11	Salvage Therapy for Childhood Medulloblastoma: A Single Center Experience. <i>Canadian Journal of Neurological Sciences</i> , 2019, 46, 403-414.	0.3	4
12	Prognostic significance of molecular subgroups of medulloblastoma in young children receiving irradiation-sparing regimens. <i>Journal of Neuro-Oncology</i> , 2019, 145, 375-383.	1.4	7
13	Sox2+ cells in Sonic Hedgehog-subtype medulloblastoma resist p53-mediated cell-cycle arrest response and drive therapy-induced recurrence. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz027.	0.4	5
14	Tumor bed proton irradiation in young children with localized medulloblastoma. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27972.	0.8	4
15	GRK2 promotes growth of medulloblastoma cells and protects them from chemotherapy-induced apoptosis. <i>Scientific Reports</i> , 2019, 9, 13902.	1.6	9
16	Molecular genetics of medulloblastoma in children: diagnostic, therapeutic and prognostic implications. <i>Future Neurology</i> , 2019, 14, FNL8.	0.9	18
17	Principles of tumorigenesis and emerging molecular drivers of SHH –activated medulloblastomas. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 990-1005.	1.7	17
18	Molecular pathology of tumors of the central nervous system. <i>Annals of Oncology</i> , 2019, 30, 1265-1278.	0.6	129

#	ARTICLE	IF	CITATIONS
19	Treatment-Induced Remission of Medulloblastoma Using a Chemotherapeutic Regimen Devoid of Vincristine in a Child with Charcotâ€“Marieâ€“Tooth Disease. <i>Current Oncology</i> , 2019, 26, 266-269.	0.9	3
20	Childhood brain tumors: current management, biological insights, and future directions. <i>Journal of Neurosurgery: Pediatrics</i> , 2019, 23, 261-273.	0.8	169
21	The genomic landscape of pediatric cancers: Implications for diagnosis and treatment. <i>Science</i> , 2019, 363, 1170-1175.	6.0	127
22	Molecular grouping and outcomes of young children with newly diagnosed ependymoma treated on the multi-institutional SJYC07 trial. <i>Neuro-Oncology</i> , 2019, 21, 1319-1330.	0.6	63
23	Desmoplastic/nodular medulloblastomas (DNMB) and medulloblastomas with extensive nodularity (MBEN) disclose similar epigenetic signatures but different transcriptional profiles. <i>Acta Neuropathologica</i> , 2019, 137, 1003-1015.	3.9	9
24	Medulloblastoma. <i>Nature Reviews Disease Primers</i> , 2019, 5, 11.	18.1	376
25	Medulloblastoma in the age of molecular subgroups: a review. <i>Journal of Neurosurgery: Pediatrics</i> , 2019, 24, 353-363.	0.8	153
26	Upfront Therapies and Downstream Effects: Navigating Late Effects in Childhood Cancer Survivors in the Current Era. <i>Current Oncology Reports</i> , 2019, 21, 104.	1.8	3
27	Radiotherapy Advances in Paediatric Medulloblastoma Treatment. <i>Clinical Oncology</i> , 2019, 31, 171-181.	0.6	22
28	Methotrexate Chemotherapy Induces Persistent Tri-glial Dysregulation that Underlies Chemotherapy-Related Cognitive Impairment. <i>Cell</i> , 2019, 176, 43-55.e13.	13.5	222
29	Genetics of Common Pediatric Brain Tumors. <i>Pediatric Neurology</i> , 2020, 104, 3-12.	1.0	14
30	Germline <i>GPR161</i> Mutations Predispose to Pediatric Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 43-50.	0.8	50
31	Subgroup-specific outcomes of children with malignant childhood brain tumors treated with an irradiation-sparing protocol. <i>Child's Nervous System</i> , 2020, 36, 133-144.	0.6	3
32	Pharmacokinetic basis for dosing high-dose methotrexate in infants and young children with malignant brain tumours. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 362-371.	1.1	17
33	The molecular biology of medulloblastoma metastasis. <i>Brain Pathology</i> , 2020, 30, 691-702.	2.1	25
34	Treatment of pediatric high-grade central nervous system tumors with high-dose methotrexate in combination with multiagent chemotherapy: A single-institution experience. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28119.	0.8	5
35	Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials. <i>Acta Neuropathologica</i> , 2020, 139, 259-271.	3.9	36
36	Time to advance methylation profiling to the forefront of primary diagnostics for childhood brain tumours. <i>The Lancet Child and Adolescent Health</i> , 2020, 4, 93-95.	2.7	0

#	ARTICLE	IF	CITATIONS
37	Medulloblastomics revisited: biological and clinical insights from thousands of patients. <i>Nature Reviews Cancer</i> , 2020, 20, 42-56.	12.8	147
38	Medulloblastoma genomics in the modern molecular era. <i>Brain Pathology</i> , 2020, 30, 679-690.	2.1	39
39	Phase II Study of Nonmetastatic Desmoplastic Medulloblastoma in Children Younger Than 4 Years of Age: A Report of the Children's Oncology Group (ACNS1221). <i>Journal of Clinical Oncology</i> , 2020, 38, 223-231.	0.8	40
40	Transcriptional profiling of medulloblastoma with extensive nodularity (MBEN) reveals two clinically relevant tumor subsets with VSNL1 as potent prognostic marker. <i>Acta Neuropathologica</i> , 2020, 139, 583-596.	3.9	13
41	The SHH/GLI signaling pathway: a therapeutic target for medulloblastoma. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 1159-1181.	1.5	33
42	Etoposide-Bound Magnetic Nanoparticles Designed for Remote Targeting of Cancer Cells Disseminated Within Cerebrospinal Fluid Pathways. <i>Frontiers in Neurology</i> , 2020, 11, 596632.	1.1	7
43	Time, pattern, and outcome of medulloblastoma relapse and their association with tumour biology at diagnosis and therapy: a multicentre cohort study. <i>The Lancet Child and Adolescent Health</i> , 2020, 4, 865-874.	2.7	48
44	Young children with medulloblastoma: important open questions and the high-risk dilemma. <i>Neuro-Oncology</i> , 2020, 22, 1723-1724.	0.6	1
45	Canadian Pediatric Neuro-Oncology Standards of Practice. <i>Frontiers in Oncology</i> , 2020, 10, 593192.	1.3	13
46	Using Pharmacology to Squeeze the Life Out of Childhood Leukemia, and Potential Strategies to Achieve Breakthroughs in Medulloblastoma Treatment. <i>Pharmacological Reviews</i> , 2020, 72, 668-691.	7.1	6
47	Patient-derived orthotopic xenografts of pediatric brain tumors: a St. Jude resource. <i>Acta Neuropathologica</i> , 2020, 140, 209-225.	3.9	45
48	Exposure's Toxicity Association of Cyclophosphamide and Its Metabolites in Infants and Young Children with Primary Brain Tumors: Implications for Dosing. <i>Clinical Cancer Research</i> , 2020, 26, 1563-1573.	3.2	14
49	Germline Elongator mutations in Sonic Hedgehog medulloblastoma. <i>Nature</i> , 2020, 580, 396-401.	13.7	94
50	Bridging the treatment gap in infant medulloblastoma: molecularly informed outcomes of a globally feasible regimen. <i>Neuro-Oncology</i> , 2020, 22, 1873-1881.	0.6	12
51	Pediatric medulloblastoma in the molecular era: what are the surgical implications?. <i>Cancer and Metastasis Reviews</i> , 2020, 39, 235-243.	2.7	2
52	Leptomeningeal malignancy of childhood: sharing learning between childhood leukaemia and brain tumour trials. <i>The Lancet Child and Adolescent Health</i> , 2020, 4, 242-250.	2.7	6
53	Immunohistochemical and nanoString-Based Subgrouping of Clinical Medulloblastoma Samples. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 437-447.	0.9	19
54	Preclinical Models of Craniospinal Irradiation for Medulloblastoma. <i>Cancers</i> , 2020, 12, 133.	1.7	4

#	ARTICLE	IF	CITATIONS
55	A rapid review of evidence and recommendations from the SIOPE radiation oncology working group to help mitigate for reduced paediatric radiotherapy capacity during the COVID-19 pandemic or other crises. <i>Radiotherapy and Oncology</i> , 2020, 148, 216-222.	0.3	18
56	Genomics Paves the Way for Better Infant Medulloblastoma Therapy. <i>Journal of Clinical Oncology</i> , 2020, 38, 2010-2013.	0.8	14
57	Pathology, diagnostics, and classification of medulloblastoma. <i>Brain Pathology</i> , 2020, 30, 664-678.	2.1	68
58	Mini-symposium in medulloblastoma genomics in the modern molecular era. <i>Brain Pathology</i> , 2020, 30, 661-663.	2.1	16
59	Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort. <i>Journal of Clinical Oncology</i> , 2020, 38, 2028-2040.	0.8	58
60	Excellent outcome of young children with nodular desmoplastic medulloblastoma treated on Head Start-III: a multi-institutional, prospective clinical trial. <i>Neuro-Oncology</i> , 2020, 22, 1862-1872.	0.6	57
61	Early and Often: The Need for Comprehensive Discussion of Treatment-Induced Cancer Late Effects. <i>Pediatrics</i> , 2020, 145, .	1.0	1
62	Brain tumors: Medulloblastoma, ATRT, ependymoma. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28395.	0.8	21
63	The molecular landscape and associated clinical experience in infant medulloblastoma: prognostic significance of second-generation subtypes. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 236-250.	1.8	12
64	The 100 Most Influential Publications on Medulloblastoma: Areas of Past, Current, and Future Focus. <i>World Neurosurgery</i> , 2021, 146, 119-139.	0.7	10
65	Deconstructing Sonic Hedgehog Medulloblastoma: Molecular Subtypes, Drivers, and Beyond. <i>Trends in Genetics</i> , 2021, 37, 235-250.	2.9	40
66	Management of high-risk medulloblastoma. <i>Neurochirurgie</i> , 2021, 67, 61-68.	0.6	15
67	Necessity for craniospinal irradiation of germinoma with positive cytology without spinal lesion on MR imaging: A controversy. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab086.	0.4	7
68	Integrated molecular analysis of adult sonic hedgehog (SHH)-activated medulloblastomas reveals two clinically relevant tumor subsets with VEGFA as potent prognostic indicator. <i>Neuro-Oncology</i> , 2021, 23, 1576-1585.	0.6	7
69	Genetic syndromes predisposing to pediatric brain tumors. <i>Neuro-Oncology Practice</i> , 2021, 8, 375-390.	1.0	3
70	Inter and intra-tumoral heterogeneity as a platform for personalized therapies in medulloblastoma. , 2021, 228, 107828.		7
71	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 807-821.	0.8	40
72	Histologic maturation of cerebral neuroblastoma following conventional chemotherapy. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29034.	0.8	1

#	ARTICLE	IF	CITATIONS
73	Histologic Correlates of Molecular Group 4 Pediatric Medulloblastoma: A Retrospective Canadian Review. <i>Pediatric and Developmental Pathology</i> , 2021, 24, 309-317.	0.5	2
74	Radiation therapy for infants with cancer. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28700.	0.8	3
75	Mesenchymal Epithelial Transition Factor Signaling in Pediatric Nervous System Tumors: Implications for Malignancy and Cancer Stem Cell Enrichment. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 654103.	1.8	5
76	The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. <i>Neuro-Oncology</i> , 2021, 23, 1231-1251.	0.6	4,534
77	Stem-Like Cell Populations, p53-Pathway Activation and Mechanisms of Recurrence in Sonic Hedgehog Medulloblastoma. <i>NeuroMolecular Medicine</i> , 2022, 24, 13-17.	1.8	5
78	Targeting cancer stem cells in medulloblastoma by inhibiting AMBRA1 dual function in autophagy and STAT3 signalling. <i>Acta Neuropathologica</i> , 2021, 142, 537-564.	3.9	21
79	Predictors of Cognitive Performance Among Infants Treated for Brain Tumors: Findings From a Multisite, Prospective, Longitudinal Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 2350-2358.	0.8	9
80	Patients With Pediatric Brain Tumor: When Do Their Delays Begin?. <i>Journal of Clinical Oncology</i> , 2021, 39, 2324-2326.	0.8	0
81	Patients, caregivers, and clinicians differ in performance status ratings: Implications for pediatric cancer clinical trials. <i>Cancer</i> , 2021, 127, 3664-3670.	2.0	15
82	Pediatric Neuro-Oncology. <i>Neurologic Clinics</i> , 2021, 39, 829-845.	0.8	12
83	Current treatments of medulloblastoma. <i>Current Opinion in Oncology</i> , 2021, 33, 615-620.	1.1	7
84	Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma. <i>JAMA Oncology</i> , 2021, 7, 1313.	3.4	61
85	Hearing loss and intellectual outcome in children treated for embryonal brain tumors: Implications for young children treated with radiation sparing approaches. <i>Cancer Medicine</i> , 2021, 10, 7111-7125.	1.3	8
86	Misactivation of Hedgehog signaling causes inherited and sporadic cancers. <i>Journal of Clinical Investigation</i> , 2019, 129, 465-475.	3.9	72
87	Targeting Upstream Kinases of STAT3 in Human Medulloblastoma Cells. <i>Current Cancer Drug Targets</i> , 2019, 19, 571-582.	0.8	10
88	Prognostic Clinical and Biologic Features for Overall Survival after Relapse in Childhood Medulloblastoma. <i>Cancers</i> , 2021, 13, 53.	1.7	10
89	Pediatric Brain Tumors. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2020, 26, 1553-1583.	0.4	6
90	Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. <i>Cancer Cell</i> , 2021, 39, 1519-1530.e4.	7.7	64

#	ARTICLE	IF	CITATIONS
91	How I Treat Medulloblastoma in Children. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 577-586.	0.1	0
92	Defining the Spectrum, Treatment and Outcome of Patients With Genetically Confirmed Gorlin Syndrome From the HIT-MED Cohort. Frontiers in Oncology, 2021, 11, 756025.	1.3	3
93	Multidisciplinary Management of Medulloblastoma: Consensus, Challenges, and Controversies. Methods in Molecular Biology, 2022, 2423, 215-235.	0.4	3
94	Molecular and clinical correlates of medulloblastoma subgroups: A narrative review. Glioma (Mumbai, India), 2021, 4, 92.	0.0	2
95	The Current Landscape of Targeted Clinical Trials in Non-WNT/Non-SHH Medulloblastoma. Cancers, 2022, 14, 679.	1.7	4
96	Tandem autologous hematopoietic stem cell transplantation for embryonal brain tumors in infants and very young children. Bone Marrow Transplantation, 2022, , .	1.3	1
97	High-Dose Chemotherapy in Children with Newly Diagnosed Medulloblastoma. Cancers, 2022, 14, 837.	1.7	12
98	Central nervous system tumors in children under 5 years of age: a report on treatment burden, survival and long-term outcomes. Journal of Neuro-Oncology, 2022, 157, 307-317.	1.4	3
99	Prognostic factors related to overall survival in adolescent and young adults with medulloblastoma: a systematic review. Neuro-Oncology Advances, 0, , .	0.4	3
100	Enhanced Survival of High-Risk Medulloblastoma-Bearing Mice after Multimodal Treatment with Radiotherapy, Decitabine, and Abacavir. International Journal of Molecular Sciences, 2022, 23, 3815.	1.8	1
101	Infant brain tumor trials: Beyond feasibility. Neuro-Oncology, 2022, , .	0.6	0
102	Diagnostic and Prognostic Implications of GNAS Inactivation in Sonic Hedgehog-Activated Medulloblastoma: Case Report with Comprehensive Molecular Profiling and Review of Literature. JCO Precision Oncology, 2022, 6, e2100403.	1.5	1
103	Subgroup-Specific Diagnostic, Prognostic, and Predictive Markers Influencing Pediatric Medulloblastoma Treatment. Diagnostics, 2022, 12, 61.	1.3	10
104	Childhood Malignant Brain Tumors: Balancing the Bench and Bedside. Cancers, 2021, 13, 6099.	1.7	15
105	A Summary of the Inaugural WHO Classification of Pediatric Tumors: Transitioning from the Optical into the Molecular Era. Cancer Discovery, 2022, 12, 331-355.	7.7	70
106	Vorinostat and isotretinoin with chemotherapy in young children with embryonal brain tumors: A report from the Pediatric Brain Tumor Consortium (PBTC-026). Neuro-Oncology, 2022, 24, 1178-1190.	0.6	13
107	Revised clinical and molecular risk strata define the incidence and pattern of failure in medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study. Neuro-Oncology, 2022, 24, 1166-1175.	0.6	2
109	Molecular Stratification of Medulloblastoma: Clinical Outcomes and Therapeutic Interventions. Anticancer Research, 2022, 42, 2225-2239.	0.5	11

#	ARTICLE	IF	CITATIONS
110	New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of Pediatric Medulloblastoma. <i>Cancers</i> , 2022, 14, 2285.	1.7	15
111	How do we approach the management of medulloblastoma in young children?. <i>Pediatric Blood and Cancer</i> , 0, , .	0.8	1
112	Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours. <i>Nature Reviews Neurology</i> , 2022, 18, 515-529.	4.9	100
113	Combined MEK and JAK/STAT3 pathway inhibition effectively decreases SHH medulloblastoma tumor progression. <i>Communications Biology</i> , 2022, 5, .	2.0	8
114	Adult Medulloblastoma: Updates on Current Management and Future Perspectives. <i>Cancers</i> , 2022, 14, 3708.	1.7	7
115	Medulloblastoma in the Modern Era: Review of Contemporary Trials, Molecular Advances, and Updates in Management. <i>Neurotherapeutics</i> , 2022, 19, 1733-1751.	2.1	13
116	Molecular classification and outcome of children with rare CNS embryonal tumors: results from St. Jude Children's Research Hospital including the multi-center SJYC07 and SJMB03 clinical trials. <i>Acta Neuropathologica</i> , 2022, 144, 733-746.	3.9	7
117	CNS penetration of methotrexate and its metabolite 7-hydroxymethotrexate in mice bearing orthotopic Group 3 medulloblastoma tumors and model-based simulations for children. <i>Drug Metabolism and Pharmacokinetics</i> , 2023, 48, 100471.	1.1	1
119	Unified rhombic lip origins of group 3 and group 4 medulloblastoma. <i>Nature</i> , 2022, 609, 1012-1020.	13.7	44
120	Improved Long-Term Survival of Patients with Recurrent Medulloblastoma Treated with a "MEMMAT-like" Metronomic Antiangiogenic Approach. <i>Cancers</i> , 2022, 14, 5128.	1.7	19
121	How Genetics and Genomics Advances Are Rewriting Pediatric Cancer Research and Clinical Care. <i>Medicina (Lithuania)</i> , 2022, 58, 1386.	0.8	2
122	Clinical and Molecular Features in Medulloblastomas Subtypes in Children in a Cohort in Taiwan. <i>Cancers</i> , 2022, 14, 5419.	1.7	0
123	Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts. <i>Acta Neuropathologica</i> , 2023, 145, 97-112.	3.9	7
124	Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation "Sparing Approaches: An International Cohort Study. <i>Journal of Clinical Oncology</i> , 2023, 41, 1921-1932.	0.8	5
125	Advances in the Treatment of Pediatric Brain Tumors. <i>Children</i> , 2023, 10, 62.	0.6	4
126	Risk prediction in early childhood SHH medulloblastoma treated with radiation-avoiding chemotherapy: Evidence for more than two subgroups. <i>Neuro-Oncology</i> , 0, , .	0.6	1
127	Medulloblastoma: Current Perspectives and Recent Advances. <i>Brain Tumor Research and Treatment</i> , 2023, 11, 28.	0.4	2
128	Unusual manifestation of cerebellopontine angle medulloblastoma with tinnitus and sensorineural hearing loss. <i>Romanian Journal of Rhinology</i> , 2023, 13, 22-31.	0.1	0

#	ARTICLE	IF	CITATIONS
129	Prognostic value of microRNA-125a expression status in molecular groups of pediatric medulloblastoma. <i>Child's Nervous System</i> , 0, , .	0.6	1
131	Prognostic factors affecting infantile medulloblastoma outcomes in the molecular era: a 12-year single-center experience from Egypt. <i>Future Oncology</i> , 0, , .	1.1	0
132	Outcomes of a radiation sparing approach in medulloblastoma by subgroup in young children: an institutional review. <i>Child's Nervous System</i> , 2023, 39, 2095-2104.	0.6	1
136	Brain and Spinal Cord Tumors of Embryonic Origin. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 405-420.	0.8	0